This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Thomas R. Tice, Ph.D.
Senior Director, Global Technical Marketing at Evonik Nutrition & Care GmbH


Dr. Tice is internationally recognized for his research and product development of complex parenteral, drug delivery dosage forms based on bioabsorbable polymer excipients. He is known for his accomplishments involving injectable, extended-release microparticles made with bioabsorbable lactide/glycolide polymers designed for systemic and local drug delivery.

He led the team and is one of the inventors that developed the first commercial, injectable, extended-release microparticle product. This product is a one-month LHRH formulation indicated for the treatment of prostate cancer (Decapeptyl® SR), a product that is still on the market today.

At Evonik, Dr. Tice, provides scientific support to Evonik’s innovation, sales, product development, research, intellectual property and M&A teams.

Dr. Tice earned his BSc in Chemistry and PhD in Biophysics from Syracuse University, New York. He held a postdoctoral fellow position at the University of Alabama at Birmingham (UAB) in Microbiology. He holds 48 US patents with many foreign equivalents and has more than 180 publications, presentations and invited lectures to his credit. He flew experiments on two Space Shuttle flights. He currently serves on the Board of McWhorter School of Pharmacy at Samford University and serves on the United States Pharmacopeia General Chapters-Dosage Forms Expert Committee and United States Pharmacopeia, Nomenclature and Labeling Expert Committee.

Agenda Sessions

  • Extended-Release of Peptides for Systemic and Local Delivery